|Mean pharmacokinetic parameter estimate of brodalumab following multiple subcutaneous and intravenous doses given to rheumatoid arthritis patientsa|
|Predicted human exposure after multiple SC (n = 6) or IV (n = 2) doses||Exposure margin based on exposure in monkeys after 3-month weekly SC doses or 1-month weekly IV dosesb|
|Dose (mg)||AUC0-tc (μg/h/ml)||Cmax (μg/ml)||AUC (μg/h/ml)||Cmax (μg/ml)|
aAUC, area under the curve; AUC0-t, area under the serum concentration time curve; Cmax, maximum serum concentration; IV, intravenous; SC, subcutaneous. bNo adverse effect level for monkeys is 90 mg/kg SC or 350 mg/kg IV. AUC0-168 hours and Cmax after the 12th dose of 90 mg/kg weekly SC were 159,000 μg/h/ml and 1,180 μg/ml, respectively. AUC0-168 hours and Cmax after fourth dose of 350 mg/kg weekly IV were 782 000 μg/h/ml and 10,100 μg/ml, respectively. cAUC0-t = AUC0-336 hours for SC cohorts and AUC0-672 hours for IV cohorts.
Martin et al.
Martin et al. Arthritis Research & Therapy 2013 15:R164 doi:10.1186/ar4347